PTC Therapeutics Announces Stock Options and RSUs for New Employees

On September 25, 2026, PTC Therapeutics, Inc. (NASDAQ: PTCT) revealed significant inducement grants aimed at enhancing its workforce. On September 22, 2026, the company approved non-statutory stock options for 51,270 shares of common stock and 37,995 restricted stock units (RSUs) designated for 37 newly hired employees. This strategic move intends to incentivize these employees as they embark on their journey with the company.

These grants are in accordance with Nasdaq Listing Rule 5635(c)(4), which permits such inducements as part of employment compensation packages. By offering stock options, PTC is not only motivating its new hires but also aligning their interests with the company's long-term success. The stock options come with an exercise price set at $65.96 per share, linked to the closing price of PTC's common stock on the grant date.

Details of the Grants

The approved stock options hold a term of 10 years and will vest over a period of four years. New employees can expect to see 25% of their granted shares vest on the first anniversary of their hiring date. The remaining shares will vest at a rate of 6.25% for every three-month period following the first anniversary, contingent upon the employee's ongoing service with the company.

Meanwhile, the RSUs will also vest over four years, with 25% vesting each year on the anniversary of the hire date. This gradual vesting schedule is designed not only to reward loyalty but also to ensure that employees remain engaged with the company's development and goals.

Mission and Vision of PTC Therapeutics

Founded with a commitment to clinical differentiation, PTC Therapeutics focuses on creating and commercializing innovative treatments for individuals suffering from rare disorders. The company prides itself on maintaining a diverse and robust pipeline of medicines, catering to the unmet needs of patients across the globe. PTC strives for excellence by leveraging its scientific knowledge and global commercial network, aiming to enhance the lives of patients through effective therapies.

To keep up with its mission, PTC Therapeutics continually seeks to attract top talent in the biopharmaceutical sector. With these recent inducements, the company reinforces its aim of supplementing its workforce with skilled individuals who can contribute to its groundbreaking work in the biopharmaceutical landscape.

For more details about PTC Therapeutics and their initiatives, interested parties can visit their official website and follow PTC on popular social media platforms like LinkedIn, Instagram, Facebook, and X.

As the biopharmaceutical landscape evolves, PTCT remains at the forefront, driving innovation and fostering relationships that ultimately lead to improved health outcomes for patients worldwide. The company is well-positioned to address the challenges posed by rare diseases and to deliver next-generation therapies that can transform patient lives.

For inquiries, investors can contact Ellen Cavaleri at +1 (615) 618-8228, and media representatives can reach out to Jeanine Clemente at +1 (908) 912-9406.

PTC Therapeutics embodies the passionate pursuit of breakthrough treatments, making strides that resonate far beyond its corporate boundaries.